Aortic valve stenosis (AS) is the most common valvular heart disease in
the elderly. Development of symptoms can include congestive heart failure,
angina (chest pain) or syncope (dizziness or fainting) in the presence
of severe aortic stenosis warrants surgical intervention to prolong life
and improve symptoms. Traditionally, surgical intervention through open
heart surgery has been the standard of care. However, elderly population,
frequently have other diseases or conditions that makes surgical intervention
very high risk. These challenges in the elderly population lead to the
development of Transcatheter Aortic Valve Replacement (TAVR). In two randomized
trials in the United States (PARTNER and CORE VALVE Trial), TAVR was compared
to traditional surgical approach in high risk patients with severe AS.
The studies showed that TAVR has similar and even better outcomes to those
patients with a traditional surgical approach. Currently, the FDA approved
TAVR for high risk patients with symptomatic severe aortic valve stenosis.
Given the remarkable outcome with TAVR, Citrus Valley Health Partners
is committed for developing an outstanding valvular program to bring this
new technology to our community. We are currently building our heart team
and partnering with our cardiologists in the community to guarantee the
success of our TAVR program.
Dr. Fahed Bitar is the Medical Director at CVHP for interventional cardiology.
He has studied in Germany with top TAVR practitioners to become certified
in doing the procedure. For more information about the Citrus Valley Heart
Center please call (626) 261-4038.